Expert choice 乳がんレジメン
商品紹介
レジメン解説を中心に、乳がん薬物療法の基本から治療マネジメントの実際までを掲載。 近年、乳がんの生物学的・遺伝学的研究、ひいては乳がん患者の病態理解が飛躍的に進み、同時に多くの乳がん治療薬や支持療法剤が上市された。そのようななか、患者一人ひとりの病態にあわせた薬物療法の選択と適切な治療マネジメントが求められる時代となった。本書では乳がん薬物療法レジメンについて、選択ポイントや治療の注意点を解説。また別途、乳がん薬物療法の基本的な考え方や知識、副作用などの治療マネジメントについても解説している。乳がん治療医はもちろんのこと、研修医や薬剤師、看護師など乳がん薬物療法に携わるすべての医療者必携の一冊。
目次
- Expert choice 乳がんレジメン
―目次―
Part.1 乳がん薬物療法の基本
1．治療の目的は何か
（何を目的としておこなうのか，どう適切に実施するか）
2．がん化学療法を継続し，適正におこなうことの重要性
3．術前薬物療法の役割
4．初期治療における病型に応じた治療戦略を知る
5．患者・家族も含めて，薬物療法への理解をどう高めるか
6．患者とのコミュニケーション
7．安心・安全・適正な薬物療法をおこなうための適切な役割分担
A．薬剤師の観点から
B．看護師の観点から
Part.2 具体的なレジメンとその解説
<初期治療>
1．AC（EC）
2．AC（EC）→PAC
3．AC（EC）→DOC
4．ddAC（EC）→ddPAC
5．TAC
6．TC
7．AC（EC）→PAC＋H
8．AC（EC）→DOC＋H
9．AC（EC）→DOC＋H＋P
10．TC＋H
11．TCH
12．PAC＋H
<転移・再発後治療>
1．AC（EC）
2．A（アンスラサイクリン系）
3．PAC
4．DOC
5．nabPAC
6．VNB
7．Gem
8．Eribulin
9．CPT-11
10．CBDCA
11．Cape
12．TS-1
13．PAC＋H＋P
14．DOC＋H＋P
15．T-DM1
16．VNB＋H
17．Cape＋H
18．Cape＋L
19．Cape＋DOC
20．PAC＋Beva
Part.3 適切な治療マネジメントのポイント
A．副作用
1．骨髄抑制
2．消化器症状
3．皮膚障害
4．過敏反応，インフュージョン・リアクション
5．心毒性
6．肺障害
7．末梢神経障害
8．血管外漏出
9．卵巣機能障害
B．患者特性
1．B型肝炎ウイルス感染
2．合併症
3．高齢者
4．生殖年齢の女性
5．アルコール不耐
C．薬剤特性
1．骨修飾薬
2．薬物相互作用
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
Part. 1 乳がん薬物療法の基本
P.15 掲載の参考文献
P.19 掲載の参考文献
1) Epelbaum R, Haim N, Ben-Shahar M et al : Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24 : 533-537, 1988
2) Weycker D, Barron R, Edelsberg J et al : Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat 133 : 301-310, 2012
3) Lyman GH, Dale DC, Crawford J : Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy : a nationwide study of community practices. J Clin Oncol 21 : 4524-4531, 2003
4) Assi H, Murray J, Boyle L et al : Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment. Support Care Cancer 22 : 3227-3234, 2014
6) Chirivella I, Bermejo B, Insa A et al : Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114 : 479-484, 2009
7) Bonneterre J, Roche H, Kerbrat P et al : Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer : 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23 : 2686-2693, 2005
8) Kosaka Y, Rai Y, Masuda N et al : Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 23 : 1137-1143, 2015
9) Piccart MJ, Klijn J, Paridaens R et al : Corticosteroids significantly delay the onset of docetaxel-induced fluid retention : Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15 : 3149-3155, 1997
P.25 掲載の参考文献
1) Wolmark N, Wang J, Mamounas E et al : Preoperative chemotherapy in patients with operable breast cancer : nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001 : 96-102, 2001
2) Bear HD, Anderson S, Brown A et al : National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide : preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 : 4165-4174, 2003
3) Rastogi P, Anderson SJ, Bear HD et al : Preoperative chemotherapy : Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26 : 778-785, 2008
4) Mieog JS. van der Hage JA, van de Velde CJ : Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev : CD005002, 2007
7) Alba E, Calvo L, Albanell J et al : GEICAM. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients : results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 23 : 3069-3074, 2012
8) Valachis A, Mauri D, Polyzos NP et al : Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer : a systematic review and meta-analysis. Breast 20 : 485-490, 2011
9) Gianni L, Eiermann W, Semiglazov V et al : Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375 : 377-384, 2010
10) Baselga J, Bradbury I, Eidtmann H et al : Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo ALTTO) : a randomised, open-label, multicentre, phase 3 trial. Lancet 379 : 633-640, 2012
11) Robidoux A, Tang G, Rastogi P et al : Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41) : an open-label, randomised phase 3 trial. Lancet Oncol 14 : 1183-1192, 2013
12) Carey LA, Berry DA, Ollila D et al : Clinical and translational results of CALGB 40601 : A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 31 (suppl) : abstr 500, 2013
13) Guarneri V, Frassoldati A, Bottini A et al : Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer : results of the randomized phase II CHER-LOB study. J Clin Oncol 30 : 1989-1995, 2012
14) de Azambuja E, Holmes AP, Piccart-Gebhart M et al : Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO) : survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 15 : 1137-1146, 2014
15) Gianni L, Pienkowski T, Im YH et al : Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13 : 25-32, 2012
16) Schneeweiss A, Chia S, Hickish T et al : Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer : a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24 : 2278-2284, 2013
17) Liedtke C, Mazouni C, Hess KR et al : Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26 : 1275-1281, 2008
18) Mayer IA, Abramson VG, Lehmann BD et al : New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res 20 : 782-790, 2014
19) von Minckwitz G, Schneeweiss A, Loibl S et al : Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto ; GBG 66) : a randomized phase 2 trial. Lancet Oncol 15 : 747-756, 2014
20) Sikov WM, Berry DA, Perou CM et al : Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once per week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer : CALGB 40603 (Alliance). J Clin Oncol 33 : 13-21, 2015
21) von Minckwitz G, Hahnen E, Fasching PA et al : Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC) : Results from GeparSixto, J Clin Oncol 32 (suppl) : abstr 1005, 2014
22) von Minckwitz G, Timms K, Untch M et al : Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC : Results from GeparSixto. J Clin Oncol 33 (suppl) : abstr 1004, 2015
23) von Minckwitz G, Eidtmann H, Rezai M et al : Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366 : 299-309, 2012
24) Bear HD, Tang G, Rastogi P et al : Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366 : 310-320, 2012
25) von Minckwitz G, Loibl S, Untch M et al : Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto). Ann Oncol 25 : 2363-2372, 2014
26) Rugo HS, Olopade O, DeMichele A et al : Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer : First efficacy results from the I-SPY 2 trial. 2013 San Antonio Breast Cancer Symposium. Abstract S5-02.
27) Cortazar P. Zhang L, Untch M et al : Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis. Lancet 384 : 164-172, 2014
28) U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) : Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer : Use as an Endpoint to Support Accelerated Approval (http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf).
P.32 掲載の参考文献
1) Osbone CK, Yochmowitz MG, Knight 3rd WA et al : The value of estrogen and progesterone receptors in the treatlnent of breast cancer. Cancer 46 : 2884-2888, 1980
2) Slamon DJ, Clark GM, Wong SG et al : Human breast cancer : correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235 : 177-182, 1987
3) Slamon DJ. Leyland-Jones B, Shak S et al : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 : 783-792, 2001
4) Allred DC, Harvey JM, Berardo MD et al : Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 : 155-168, 1998
5) Wolff AC, Hammond EH. Hicks DG et al : Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 31 : 399. 7-4013. 2013
7) The Cancer Genome Atlas Network : Comprehensive molecular portraits of human breast tumours. Nature 490 : 61-70, 2012
8) Anderson WF, Rosenberg PS, Prat A et al : How many etiological subtypes of breast cancer : two, three, four, or more? J Natl Cancer Inst 106 : dju165, 2014
9) Kennecke H, Yerushalmi R, Woods R et al : Metastatic behavior of breast cancer subtypes. J Clin Oncol 28 : 3271-3277, 2010
10) Parker JS, Mullins M, Cheang MCU et al : Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol 27 : 1160-1167, 2009
11) Voduc KD, Cheang MCU, Tyldesley S et al : Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28 : 1684-1691, 2010
12) Nguyen B, Cusumano PG, Deck K et al : Comparison of molecular subtyping with BluePrint, MammaPrint. and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol 19 : 3257-3263, 2012
13) Bastien R, Rodriguez-Lescure A, Ebbert M et al : PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 5 : 44, 2012
14) Dowsett M, Sestak I, Lopez-Knowles E et al : Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31 : 2783-2790, 2013
15) Albain KS, Barlow WE, Shak S et al : Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive. oestrogen-receptor-positive breast cancer on chemotherapy : a retrospective analysis of a randomised trial. Lancet Oncol 11 : 55-65, 2010
16) Polley MYC, Leung SCY. McShane LM et al : An international Ki67 reproducibility study. J Natl Cancer Inst 105 : 1897-1906, 2013
17) Maisonneuve P, Disalvatore D, Rotmensz N et al : Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 16 : R65. 2014
18) Lehmann BD, Bauer JA, Chen Xi et al : Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121 : 2750-2767, 2011
19) Rouzier R, Perou CM, Symmans WF et al : Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 : 5678-5685, 2005
20) von Minckwitz G, Untch M, Bllohmer J-U et al : Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30 : 1786-1804, 2012
22) Stevens KN, Vachon CM, Couch FJ : Genetic susceptibility to triple-negative breast cancer. Cancer Res 73 : 2025, 2013
23) von Minckwitz G, Schneeweiss A, Loibl S et al : Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto : GBG 66) : a randomised phase 2 trial. Lancet Oncol 15 : 747-756, 2014
24) Sikov WM, Berry DA, Perou CM et al : Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer : CALGB 40603 (Alliance). J Clin Oncol 33 : 13-21, 2015
25) Ando M, Yamauchi H, Aogi K et al : Randomized phase II study of weekly paclitaxel with and without Carboplatin followed by Cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IV A breast cancer without HER2 overexpression. Breast Cancer Res Treat 145 : 401-409, 2014
26) Prat A, Bianchini G, Thomas M et al : Research-based PAM50 subtype predictor indentifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 20 : 511-521, 2014
27) Majewski IJ, Nuciforo P, Mittempergher L et al : PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 33 : 1334-1339, 2015
28) Paik S, Tang G, Shak S et al : Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 : 3726-3734, 2006
29) Sparano JA, Gray RJ, Makower DF et al : Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med, 2015 [Epub ahead of print]
30) Early Breast Cancer Trialists' Collaborative Group (EBCTCG) : Comparisons between different polychemotherapy regimens for early breast cancer : meta-analyses of ong-term outcome among 100,000 women in 123 randomised trials. Lancet 379 : 432-444, 2012
P.36 掲載の参考文献
1) Leigh S : Cancer Survivorship : A Nursing Perspective. Cancer Survivorship : Today and Tomorrow, ed. by Ganz P, Springer, New York, 2007, pp.8-13
2) O'Conncer A (有森直子訳) : Ottawa Personal Decision Guide (オタワ個人意思決定ガイド), 2004〔http://hdl.handle.net/10285/4637〕
P.41 掲載の参考文献
1) Baile WF, Buckman R, Lenzi R et al : SPIKES-A six-step protocol for delivering bad news : application to the patient with cancer. Oncologist 5 : 302-311, 2000
2) Fujimori M, Parker PA, Akechi T et al : Japanese cancer patients' communication style preferences when receiving bad news. Psychooncology 16 : 617-625, 2007
3) Fujimori M, Shirai Y, Asai M et al : Effect of communication skills training program for oncologists based on patient preferences for communication when receiving bad news : a randomized controlled trial. J Clin Oncol 32 : 2166-2172, 2014
P.46 掲載の参考文献
1) Stacey D, Bennett CL, Barry MJ et al : Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 1 : CD001431, 2014
2) Joseph O, Jacobson, Martha Polovich et al : American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Clin Oncol 32 : 5469-5475, 2009
3) Barry MJ, Edgman-Levitan S : Shared decision making-the pinnacle of patient-centered care. N Engl J Med 366 : 780-781, 2012
4) 本山清美 : 副作用を最小限にするためのセルフケア支援. がん化学療法ケアガイド, 濱口恵子, 本山清美編, 中山書店, 東京, 2012, pp.9-17
Part. 2 具体的なレジメンとその解説
P.118 掲載の参考文献
1) Fisher B, Brown AM, Dimitrov NV et al : Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors : results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8 : 1483-1496, 1990
2) Fisher B, Anderson S, Tan-Chiu E et al : Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer : findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19 : 931-942, 2001
3) Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C et al : Comparisons between different polychemotherapy regimens for early breast cancer : meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379 : 432-444, 2012
4) Piccart MJ, Di Leo A, Beauduin M et al : Phase m trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19 : 3103-3110, 2001
5) Shulman LN, Berry DA, Cirrincione CT et al : Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes : CALGB 40101 (Alliance). J Clin Oncol 31 : 2311-2317, 2014
6) Henderson IC, Berry DA, Demetri GD et al : Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 : 976-983, 2003
7) Mamounas EP, Bryant J, Lembersky B et al : Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer : results from NSABP B-28. J Clin Oncol 23 : 3686-3696, 2005
8) De Laurentiis M, Cancello G, D'Agostino D et al : Taxane-based combinations as adjuvant chemotherapy of early breast cancer : a meta-analysis of randomized trials. J Clin Oncol 26 : 44-53, 2008
9) Sparano JA, Zhao F, Martino S et al : Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol 33 : 2353-2360, 2015
10) Hayes DF, Thor AD, Dressler LG et al : HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357 : 1496-1506, 2007
11) Penault-Llorca F, Andre F, Sagan C et al : Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27 : 2809-2815, 2009
12) Martin M, Pienkowski T, Mackey J et al : Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 : 2302-2313, 2005
13) Roche H, Fumoleau P, Spielmann M et al : Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients : the FNCLCC PACS 01 Trial. J Clin Oncol 24 : 5664-5671, 2006
14) Sparano JA, Wang M, Martino S et al : Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358 : 1663-1671, 2008
15) Nitz U, Gluz O, Huober J et al : Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer : efficacy and predictive value of Ki67 expression. Ann Oncol 25 : 1551-1557, 2014
16) Watanabe T, Kuranami M, Inoue K et al : Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer : Results of N-SAS-BC02 trial. J Clin Oncol 27 : 15s, abstr 516, 2009
17) Toi M, Nakamura S, Kuroi K et al : Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110 : 531-539, 2008
18) Harvey V, Mouridsen H, Semiglazov V et al : Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24 : 4963-4970, 2006
19) Del Mastro L, De Placido S, Brazzi P et al : Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer : an open-label, 2×2 factrial, randomized phase 3 trial. Lancet 385 : 1863-1872, 2015
20) Petrelli F, Cabiddu M, Coinu A et al : Adjuvant dose-dense chemotherapy in breast cancer : a systematic review and meta-analysis of randomized trials. Breast cancer Res Treat 151 : 251-259, 2015
21) Budd GT, Barlow WE, Moore HC et al : SWOG S0221 : A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33 : 58-64, 2015
22) Martin M, Segui MA, Anton A et al : Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363 : 2200-2210, 2010
23) Eiermann W, Pienkowski T, Crown J et al : Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-nomal, node positive breast cancer : BCIRG-005 trial. J Clin Oncol 29 : 3877-3884, 2011
24) Jones S, Holmes FA, O'Shaughnessy J et al : Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide : 7-year follow-up of US Oncology research trial 9735. J Clin Oncol 27 : 1177-1183, 2009
25) Jones SE, Collea R, Paul D et al : Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer : a single-group, open-label, phase 2 study. Lancet Oncol 14 : 1121-1128, 2013
26) Bonadonna G : Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52 : 2127-2137, 1992
28) Ryberg M, Nielsen D, Skovsgaard T et al : Epirubicin cardiotoxicity : an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16 : 3502-3508, 1998
29) Mamounas EP, Bryant J, Lembersky B et al : Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer : results from NSABP B-28. J Clin Oncol 23 : 3686-3696, 2005
30) Green MC, Buzdar AU, Smith T et al : Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23 : 5983-5992, 2005
31) Swain SM, Jeong J, Geyer CE et al : NSABP B-30 : definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Res 69 : 75, 2009
32) Bines J, Earl H, Buzaid AC et al : Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer : does the sequence matter? Ann Oncol 25 : 1079-1085, 2014
33) Wildiers H, Forceville K, Paridaens R et al : Taxanes and anthracyclines in early breast cancer : which first? Lancet Oncol 11 : 219-220, 2010
34) Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al : Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 : 1659-1672, 2005
35) Romond EH, Perez EA, Bryant J et al : Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 : 1673-1684, 2005
36) Gianni L, Eiermann W, Semiglazov V et al : Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375 : 377-384, 2010
37) Moja L, Tagliabue L, Balduzzi S et al : Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4 : CD006243, 2012
38) Slamon D, Eiermann W, Robert N et al : Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 : 1273-1283, 2011
39) Slamon DJ, Leyland-Jones B, Shak S et al : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 : 783-792, 2001
40) Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al : 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA) : an open-label, randomised controlled trial. Lancet 382 : 1021-1028, 2013
41) Pivot X, Romieu G, Debled M et al : 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE) : a randomised phase 3 trial. Lancet Oncol 14 : 741-748, 2013
42) Gianni L, Pienkowski T, Im YH et al : Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13 : 25-32, 2012
43) Schneeweiss A, Chia S, Hickish T et al : Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer : a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24 : 2278-2284, 2013
44) von Minckwitz G, Baselga J, Bradbury I et al : Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer : APHINITY (BIG 4-11/BO25126/TOC4939g). Cancer Res 71 : OT1-02-04, 2011
45) Jones SE, Collea R, Paul D et al : Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer : a single-group, open-label, phase 2 study. Lancet Oncol 14 : 1121-1128, 2013
46) Coudert BP, Largillier R, Arnould L et al : Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer : results of the GETN (A) -1 trial. J Clin Oncol 25 : 2678-2684, 2007
47) Tolaney SM, Barry WT, Dang CT et al : Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372 : 134-141, 2015
48) Gonzalez-Angulo AM, Litton JK, Broglio KR et al : High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27 : 5700-5706, 2009
49) 制吐薬適正使用ガイドライン 2015年10月第2版, 日本癌治療学会編, 金原出版, 東京, 2015
50) G-CSF適正使用ガイドライン 2013年度版, 日本癌治療学会編, 金原出版, 東京, 2013
51) Yokose N, Ogata K, Tamura H et al : Pulmonary Toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. Br J Cancer 77 : 2286-2290, 1998
52) Lyman GH, Dale DC, Wolff DA et al : Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor : a systematic review. J Clin Oncol 28 : 2914-2924, 2010
53) Kosaka Y, Rai Y, Masuda N et al : Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 23 : 1137-1143, 2015
54) FDA approval for trastzumab revised 2010.
55) http://www.nejm.org/doi/suppl/10.1056/NEJMoa0910383/suppl_file/nejmoa0910383_protocol.pdf
P.121 掲載の参考文献
1) Biganzoli L, Cufer T, Bruning P et al : Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer : The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20 : 3114-3121, 2002
2) Katsumata N, Watanabe T, Minami H et al : Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer : Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol 20 : 1210-1215, 2009
3) Langley RE, Carmichael J, Jones AL et al : Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer : United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 23 : 8322-8330, 2005
4) Piccart-Gebhart MJ, Burzykowski T, Buyse M et al : Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26 : 1980-1986, 2008
5) Hortobagyi GN : Treatment of breast cancer. N Engl J Med 339 : 974-984, 1998
6) Hoogstraten B, George SL, Samal B et al : Combination hemotherapy and adriamycin in patients with advanced reast cancer. A Southwest Oncology Group study. Cancer 38 : 13-20, 1976
7) Steiner R, Stewart JF, Cantwell BM et al : Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19 : 1553-1557, 1983
8) Chan S, Friedrichs K, Noel D et al : Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 : 2341-2354, 1999
9) French Epirubicin Study Group : A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol 9 : 305-312, 1991
10) Bastholt L, Dalmark M, Gjedde SB et al : Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer : a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14 : 1146-1155, 1996
11) Berruti A, Bitossi R, Gorzegno G et al : Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine : final results of a phase III study with a factorial design. J Clin Oncol 20 : 4150-4159, 2002
12) Lord S, Ghersi D, Gattellari M et al : Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev : CD003367, 2004
13) Carrick S, Parker S, Thornton CE et al : Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev : CD003372, 2009
14) Gundersen S, Kvinnsland S, Klepp O et al : Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22 : 1431-1434, 1986
15) Joensuu H, Holli K, Heikkinen M et al : Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer : a prospective randomized trial. J Clin Oncol 16 : 3720-3730, 1998
16) Gasparini G, Dal Fior S, Panizzoni GA et al : Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol 14 : 38-44, 1991
17) Bristow MR, Mason JW, Billingham ME et al : Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102 : 709-718, 1981
18) Swain SM, Whaley FS, Ewer MS et al : Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three trials. Cancer 97 : 2869-2879, 2003
19) Ryberg M, Nielsen D, Cortese G et al : New insight into epirubicin cardiac toxicity : competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100 : 1058-1067, 2008
20) Seidman AD, Berry D, Cirrincione C et al : Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors : final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26 : 1642-1649, 2008
21) Ghersi D, Wilcken N, Simes RJ : A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93 : 293-301, 2005
22) ten Tije AJ, Smorenburg CH, Seynaeve C et al : Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 40 : 352-357, 2004
23) Del Mastro L, Perrone F, Repetto L et al : Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients : a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 16 : 253-258, 2005
24) Hara F, Matsubara N, Saito T et al : Randomaized phade III study of taxane versus TS-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC). J Clin Oncol 32 (5S) : 1012, 2014
25) Harvey V, Mouridsen H, Cold S et al : Phase III trial comparing these doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24 : 4963-4970, 2006
26) Gradishar WJ, Tjulandin S, Davidson N et al : Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 : 7794-7803, 2005
27) Gradishar WJ, Krasnojon D, Cheporov S et al : Significantly longer progression-free survival with nabPaclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27 : 3611-3619, 2009
28) Rugo HS, Barry WT, Moreno-Aspitia A et al : Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer : CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 33 : 2361-2369, 2015
29) Untch M, Jackisch C, Schneeweiβ A et al : A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto) ; GBG 69. Cancer Res 75 : S2-S07, 2015
30) Gasparini G, Caffe O, Barni S et al : Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients : a phase II study. J Clin Oncol 12 : 2094-2101, 1994
31) Toi M, Saeki T, Aogi K eta l : Late Phase II Clinical Study of Vinorelbine Monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol 35 : 310-315, 2005
32) Martin M, Ruiz A, Munoz M et al : Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes : final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8 : 219-225, 2007
33) Suzuki Y, Tokuda Y, Fujiwara Y et al : Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after antheracycline and taxane treatment. Jpn J Clin Oncol 39 : 699-706, 2009
34) 科学的根拠に基づく乳癌診療ガイドライン 1 治療編 2015年版, 日本乳癌学会編, 金原出版, 東京, 2015
35) Rha SY, Moon YH, Jeung HC et al : Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90 : 215-221, 2005
36) Spielmann M, Llombart-Cussac A, Kalla S et al : Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60 : 303-307, 2001
37) NCCN腫瘍学臨床実践ガイドライン乳癌 2014年 第1版, National Comprehensive Cancer Network
38) Takao S, Tokuda Y, Saeki T et al : Long-term gemcitabine administration in heavily pretreated Japanese patients with metastatic breast cancer : additional safety analysis of a phase II study. Breast Cancer 19 : 335-342, 2012
39) Cortes J, O'Shaughnessy J, Loesch D et al : Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE) : a phase 3 open-label randomised study. Lancet 377 : 914-923, 2011
40) 田口鐵男, 吉田豊, 泉雄勝ほか : 進行・再発乳癌に対するCPT-11 (塩酸イリノテカン) の前期第II相臨床試験. 癌と化療 21 : 83-90, 1994
41) 田口鐵男, 冨永健, 小川一誠ほか : 再発・進行乳癌に対するCPT-11 (塩酸イリノテカン) の後期第II相臨床試験. 癌と化療 21 : 1017-1024, 1994
42) Perez EA, Hillman DW, Mailliard JA et al : Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22 : 2849-2855, 2004
43) O'Brien ME, Talbot DC, Smith IE : Carboplatin in the treatment of advanced breast cancer : a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11 : 2112-2117, 1993
44) Kolaric K, Vukas D : Carboplatin activity in untreated metastatic breast cancer patients--results of a phase II study. Cancer Chemother Pharmacol 27 : 409-412, 1991
45) Tutt A, Killbum L : TNT : A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast cancer. In. San Antonio Breast Cancer Symposium 2014
46) Fumoleau P, argiller R, Clippe C et al : Multicenter, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast. Eur J Cancer 40 : 536-542, 2004
47) Kaufman PA, Awada A, Twelves C et al : Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33 : 594-601, 2015
48) 適正使用ガイド ゼローダ(R) 錠300 乳癌 2007年12月作成
49) Saeki T, Takashima S, Sano M et al : A late Phase II clinical study of S-1 in patients with progressed, refractory breast cancer. Jpn J Cancer Chemother 31 : 539-547, 2004
50) Hino M, Saeki T, Sato Y et al : Late phase II study of S-1 in patients with taxane resistant breast cancer. J Clin Oncol 22 (14S) : 745, 2004
51) Yamamoto D, Iwase S, Yoshida H et al : Efficacy of S-1 in patients with capecitabine-resistant breast cancer research Network (JBCRN) 04-1 trial. Anticancer Res 30 : 3827-3832, 2010
52) Lillian MS, Iyengar N, Sarat C : Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC) : Updated progression-free survival eith overall survival result. J Clin Oncol 33 (suppl) : abstr 607, 2015
53) Dang C, Iyengar N, Datko F et al : Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33 : 442-447, 2015
54) Baselga J, Cortes J, Kim SB et al : Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366 : 109-119, 2012
55) Verma S, Miles D, Gianni L et al : Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 : 1783-1791, 2012
56) Krop IE, Kim SB, Gonzalez-Martin A et al : Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA) : a randomised, open-label, phase 3 trial. Lancet Oncol 15 : 689-699, 2014
57) Burris HA 3rd, Rugo HS, Vukelja SJ et al : Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29 : 398-405, 2011
58) Burstein HJ, Keshaviah A, Baron AD et al : Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer : the trastuzumab and vinorelbine or taxane study. Cancer 110 : 965-972, 2007
59) Andersson M, Lidbrink E, Bjerre K et al : Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer : the HERNATA Study. J Clin Oncol 29 : 264-271, 2011
60) Bartsch R, Wenzel C, Altorjai G et al : Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25 : 3853-3858, 2007
61) Schaller G, Fuchs I, Gonsch T et al : Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25 : 3246-3250, 2007
62) Yamamoto D, Iwase S, Kitamura K et al : A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer : Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 61 : 509-514, 2008
63) Ishida T, Kiba T, Takeda M et al : Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol 64 : 361-369, 2009
64) von Minckwitz G, du Bois A, Schmidt M et al : Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer : a german breast group 26/breast international group 03-05 study. J Clin Oncol 27 : 1999-2006, 2009
65) von Minckwitz G, Schwedler K, Schmidt M et al : Trastuzumab beyond progression : overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 47 : 2273-2281, 2011
66) Pivot X, Manikhas A, Zurawski B et al : CEREBEL (EGF111438) : A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33 : 1564-1573, 2015
67) Geyer CE, Forster J, Lindquist D et al : Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 : 2733-2743, 2006
68) Cameron D, Casey M, Oliva C et al : Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer : final survival analysis of a phase III randomized trial. Oncologist 15 : 924-934, 2010
69) Iwata H, Fujii H, Masuda N et al : Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine : results from 51 Japanese patients treated in a clinical study. Breast Cancer 22 : 192-200, 2015
70) Sawada N, Ishikawa T, Fukase Y et al : Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4 : 1013-1019, 1998
71) O'Shaughnessy J, Miles D, Vukelja S et al : Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer : phase III trial results. J Clin Oncol 20 : 2812-2823, 2002
72) Beslija S, Obralic N, Basic H et al : Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T) : XT vs. T followed by×after progression as first-line therapy for patients with metastatic breast cancer. J Clin Oncol 24 (Suppl) : abstr 571, 2006
73) Sato N, Yamamoto D, Rai Y et al : Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline : results from a randomized phase III study (JO21095). Poster presented at the 2012 San Antonio Breast Cancer Symposium ; December 4-8, 2012 ; San Antonio, TX. Poster P1-12-01.
74) Miller K, Wang M, Gralow J et al : Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 : 2666-2676, 2007
75) Miles DW, Chan A, Dirix LY et al : Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28 : 3239-3247, 2010
76) Robert NJ, Dieras V, Glaspy J et al : RIBBON-1 : randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29 : 1252-1260, 2011
77) Aogi K, Masuda N, Ohno S et al : First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer : efficacy and safety results from a large, open-label, single-arm japanese study. Breast Cancer Res Treat 129 : 829-838, 2011
78) Mielke S, Sparreboom A, Mross K : Peripheral neuropathy : a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42 : 24-30, 2006
79) ナベルビン(R) 添付文書 2015年2月改訂 (第13版)
80) Pollera CF, Ceribelli A, Crecco M et al : Prolonged infusion gemcitabine : a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Investigational New Drugs 15 : 115-121, 1997
81) 桶野光生, 治田匡平, 吉村忠道ほか : 塩酸ゲムシタビン投与中に起こる血管痛の評価とその対策. 日病薬師会誌 44 : 801-803, 2008
82) Satoh T, Ura T, Yamada Y et al : Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102 : 1868-1873, 2011
83) Mochizuki Y, Ohashi N, Kojima H et al : CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702). Cancer Chemother Pharmacol 72 : 629-635, 2013
84) パラプラチン(R) 添付文書 2014年8月改訂 (第17版)
85) Markman M : The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management. Gynecol Oncol 107 : 163-165, 2007
86) Rose PG, Fusco N, Smrekar M et al : Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89 : 429-433, 2003
87) Yamada T, Watanabe H, Yano T et al : The timing of expression of blood coagulation abnormality in patients treated with warfarin and S-1 concomitantly. 薬誌 130 : 955-960, 2010
88) ティーエスワン(R) インタビューフォーム 改訂第22版, 2015
89) Jatoi A, Thrower A, Sloan JA et al : Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 15 : 1016-1022, 2010
90) Lacouture ME, Laabs SM, Koehler M et al : Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 114 : 485-493, 2009
91) Simonart T, Dramaix M, De Maertelaer V : Efficacy of tetracyclines in the treatment of acne vulgaris : a review. Br J Dermatol 158 : 208-216, 2008
92) 適正使用ガイド アバスチン(R) 点滴静注用 100 mg/4 mL 乳癌 2014年6月改訂
Part. 3 適切な治療マネジメントのポイント
P.132 掲載の参考文献
1) Feher O, Vodvarka P, Jassem J et al : First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer : a multicenter, randomized, phase III study. Ann Oncol 16 : 899-908, 2005
2) Verma S, Miles D, Gianni L et al : Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 : 1783-1791, 2013
3) Martin M, Segui MA, Anton A et al : Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363 : 2200-2210, 2010
4) Toi M, Nakamura S, Kuroi K et al : Phase II study ofpreoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 110 : 531-539, 2008
5) Kosaka Y, Rai Y, Masuda N et al : Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 23 : 1137-1143, 2015
6) Cortes J, O'Shaughnessy J, Loesch D et al : Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE) : a phase 3 open-label randomised study. Lancet 177 : 914-923, 2011
7) Holmes FA, O'Shoughnessy JA, Vukelia S et al : Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20 : 727-731, 2002
8) Masuda N, Tokuda N, Nakamura S et al : Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy : a randomized controlled trial. Support Care Cancer 23 : 2891-2898, 2015
9) Klastersky J, Paesmans M, Rubenstein EB et al : The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 : 3038-3051, 2000
10) Freifeld A, Marchigiani D, Walsh T et al : A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341 : 305-311, 1999
11) Kern WV, Marchetti O, Drgona L et al : Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer : A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectious Diseases Group Trial XV. J Clin Oncol 31 : 1149-1156, 2013
12) Bow EJ, Rotstein C, Noskin GA et al : A randomized. open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43 : 447-459, 2006
P.135 掲載の参考文献
1) Basch E, Prestrud AA, Hesketh PJ et al : Antiemetics : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 29 : 4189-4198, 2011
2) Peterson DE, Bensadoun RJ, Roila F et al : Management of oral and gastrointestinal mucositis : ESMO Clinical Practice Guidelines. Ann Oncol 22 : 78-84, 2011
3) 重篤副作用疾患別対応マニュアル 抗がん剤による口内炎 厚生労働省 (http://www.mhlw.go.jp/topics/2006/11/tp1122-11.html)
4) Benson AB 3rd, Ajani JA, Catalano RB et al : Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea J Clin Oncol 22 : 2918-2926, 2004
5) 新臨床腫瘍学-がん薬物療法専門医のために-改訂第3版, 日本臨床腫瘍学会編, 南江堂, 東京, 2012, pp.652
6) Mori K, Kondo T, Kamiyama Y et al : Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51 : 403-406, 2003
7) がん患者の消化器症状の緩和に関するガイドライン 2011年版, 緩和医療学会緩和医療ガイドライン作成委員会編, 金原出版, 東京, 2011, pp.58-61
8) アミティーザ(R) カプセル 添付文書
P.139 掲載の参考文献
1) Betticher DC, Delmore G, Breitenstein U et al : Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 21 : 2565-2573, 2013
2) van den Hurk CJ, van den Akker-van Marle ME, Breed WP et al : Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer. Eur J Oncol Nurs 17 : 536-540, 2013
3) Duvic M, Lemak NA, Valero V et al : A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35 : 74-78, 1996
4) Shin H, Jo SJ, Kim do H et al : Efficacy of interventions for prevention of chemotherapy-induced alopecia : a systematic review and meta-analysis. Int J Cancer 136 : 2015
5) Robert C, Sibaud V, Mateus C et al : Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 16 : e181-e189, 2015
7) Wolf SL, Qin R, Menon SP et al : Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome : North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28 : 5182-5187, 2010
8) Macedo LT, Lima JP, dos Santos LV et al : Prevention strategies for chemotherapy-induced hand-foot syndrome : a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 22 : 1585-1593, 2014
9) Chen M, Zhang L, Wang Q, Shen J : Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy : a systematic review. PLoS One 20 : e72245, 2013
10) Chen M, Crowson AN, Woofter M et al : Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus : report of 4 cases. J Rheumatol 31 : 818, 2004
11) Weger W, Kranke B, Gerger A et al : Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J Am Acad Dermatol 59 (2 Suppl 1) : S4-S6, 2008
P.143 掲載の参考文献
1) 小暮友毅, 仁科智裕 : アレルギー症状, infusion reaction. がん薬物療法の支持療法マニュアル. 鈴木賢一, 中垣繁, 米村雅人編, 南江堂, 東京, 2013, pp96-106
2) 岡元るみ子 : 過敏反応, インフュージョン・リアクション. がん化学療法副作用対策ハンドブック. 岡元るみ子, 佐々木常雄編, 羊土社, 東京, 2012, pp32-38
P.147 掲載の参考文献
1) 組橋由記, 石倉久嗣 : 心毒性. がん薬物療法の支持療法マニュアル. 鈴木賢一, 中垣繁, 米村雅人編, 南江堂, 東京, 2013, pp132-138
2) 澤田武志, 佐々木栄作 : 循環器障害. がん化学療法副作用対策ハンドブック. 岡元るみ子, 佐々木常雄編, 羊土社, 東京, 2012, pp66-69
3) 北村和広, 弦間昭彦 : 心毒性. がん診療UP TO DATE. がん診療UP TO DATE編集委員会編, 日経BP社, 東京, 2013
P.150 掲載の参考文献
1) 齋藤好信, 弦間昭彦 : 肺毒性. がん診療UP TO DATE. がん診療UP TO DATE編集委員会編, 日経BP社, 東京, 2013
鈴木賢一, 内藤立暁 : 薬剤性肺障害. がん薬物療法の支持療法マニュアル. 鈴木賢一, 中垣繁, 米村雅人編, 南江堂, 東京, 2013, pp154-163
山本亜也, 細見幸生 : 肺毒性. がん化学療法副作用対策ハンドブック. 岡元るみ子, 佐々木常雄編, 羊土社, 東京, 2012, pp70-73
P.152 掲載の参考文献
重篤副作用疾患別対応マニュアル「末梢神経障害」厚生労働省ホームページ
新がん化学療法ベスト・プラクティス, 佐々木常雄, 岡元るみ子編, 照林社, 東京, 2012, pp.188-195
がん化学療法副作用対策ハンドブック, 岡元るみ子, 佐々木常雄編, 羊土社, 東京, 2010, pp.90-94
がん化学療法看護ポケットナビ, 本山清美, 遠藤久美編, 中山書店, 東京, 2011, pp.227-230
がん化学療法・バイオセラピー看護実践ガイドライン, 佐藤禮子監訳, 医学書院, 東京, 2009, pp.261
外来がん化学療法. 田中登美編, 学研, 東京, 2010, pp.186-188
Hershman DL, Lacchetti C, Dnorkin RH et al : Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult Cancers : american society of clinical oncology clinical practice Guideline. J Clin Oncol 32 : 1941-1962. 2014
がん診療UP TO DATE, がん診療UP TO DATE編集委員会編, 日経BP社, 東京, 2013, pp.810-823
P.156 掲載の参考文献
1) Perez Fidalgo JA, Garcia Fabregat L, Cervantes A et al : Management of chemotherapy extravasation : ESMO-EONS Clinical Practice Guidelines. Ann Oncol 23 : 167-173, 2012
2) Narducci F, Jean-Laurent M, Boulanger L et al : Totally implantable venous access port systems and risk factors for complications : a one-year prospective study in a cancer centre. Eur J Surg Oncol 37 : 913-918, 2011
3) がん診療レジデントマニュアル 第6版, 国立がん研究センター内科レジデント編. 医学書院, 東京, 2013, pp.408-413
4) サビーン(R) 添付文書 : 2014年5月改訂 (第2版)
5) Mouridsen HT, Langer SW, Buter J et al : Treatment of anthracycline extravasation with Savene (dexrazoxane) : results from two prospective clinical multic entre studies. Ann Oncol 18 : 546-550, 2007
6) 外来がん化学療法看護ガイドライン 1 2014年版, 日本がん看護学会編, 金原出版, 東京, 2014, pp.55-56
P.160 掲載の参考文献
1) Gao X, Petroff BK, Oluola O et al : Endocrine disruption by indole-3-carbonik and tamoxifen : blockage of ovulation. Toxic Appl Pharmacol 183 : 179-188, 2002
2) Tsujioka S, Ban Y, Wise LD et al : Collaborative work on evaluation of ovarian toxicity. 3) Effects of 2- or 4-week repeated-dose toxicity and fertility studies with tamoxifen in female rats. J Toxicol Sci 34 (Suppl 1) : SP43-SP51, 2009
3) Kaufmann M, Jonat W, Blamey R et al : Survival analysis from ZEBRA study, goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39 : 1711-1717, 2003
4) Abusief ME, Missmer SA, Ginsburg ES et al : The effcts of paclitaxel, dose density, and trastuzumab on treatment-related amennorhea in Premenoposal women with breast cancer. Cancer 116 : 791-798, 2010
5) Kalicgu-Philosoph L, Roness H, Carmely A et al : Cyclophosphamide triggers follicle activation and burn out AS101 prevents follicle loss and preserves fertility. Sci Trans Med 5 : 185ra62, 2013
6) Morgan S, Lopes F, Gourley C et al : Cisplatin and doxorubicin induce distinct mechanismas of ovarian follicle loss ; imatinib provides selective protection only against cisplatin. PLoS One 8 : e70117, 2013
7) Meirow D, Biederman H, Anderson RA et al : Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol 53 : 727-739, 2010
8) Bar-Joseph, Ben-Aharon I, Rizel S et al : Doxorubicin-induced apoptosis in germinal vesicle oocytes. Reprod Toxicol 30 : 566-572, 2010
9) Ben-Aharon I, Bar-Joseph H, Tzarfaty G et al : Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol 8 : 20, 2010
10) Bar-Joseph H, Ben-Aharon I, Tzabari M et al: In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 6 : e23492, 2011
11) Meirow D, Dor J, Kaufman B et al : Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 22 : 1626-1633, 2007
12) Oktem O, Oktay K : Quantative assessment of impact of chemotherapy ovarian follicle reserve and stromal function. Cancer 110 : 2222-2229, 2007
13) Tsai-Turton M, Luong BT, Tan Y et al : Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci 98 : 216-230, 2007
14) Devine PJ, Perreault SD, Luderer U : Roles of reactive oxygen species abd antioxidants in ovarian toxicity. Biol Reprod 86 : 27, 2012
15) Yeh J, Kim B, Liang YJ et al : Mullerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochem Biophys Res Commun 348 : 337-344, 2006
16) Yeh J, Kim BS, Liang YJ et al : Baseline and stimulated serum inhibin levels as a biomarkers of cisplatin-induced ovarian damage in female rats. Am J Obstet Gynecol 198 : e1-e6, 2008
17) Yeh J, Kim BS, Peresie J et al : Declines in levels of hyperpolarization-activated cation channels in the rat ovary after cisplatin exposure. Reprod Sci 16 : 986-994, 2009
18) Yucebilgin MS, Terek MC, Ozsaran A et al : Effect of chemotherapy on primordial follicular reserve if rat : an animal model og premature ovarian failure and infertility. Aust N K Obstet Gynaecol 44 : 6-9, 2004
19) Tarumi W, Suzuki N, Takahashi N et al : Ovarian toxicity of paclitaxel and effect on fertility in the rat. J Obstet Gynaecol Res 35 : 414-420, 2009
20) Zhou WB, Yin H, Liu XA et al : Analysis of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel, navelbine in younger breast cancer patients. BMC Cancer 10 : 281, 2010
21) Azem F, Amit A, Merimsky O et al : Sccessful transfer of frozen-thowed embryos obtained after aubtotal colectomy for colorectal cancer and before fluorouracil-based chemotherapy. Gynecol Oncol 93 : 263-265, 2004
がん・生殖医療 妊孕性温存の診療. 鈴木直, 竹原祐志編, 医歯薬出版, 東京, 2013
科学的根拠に基づく乳癌診療ガイドライン 1 治療編 2015年版 日本乳癌学会編, 金原出版, 東京, 2015
乳がん患者の妊娠出産と生殖医療に関する診療の手引き 2014年版, 「乳癌患者の妊孕性保持のための治療選択・患者支援プログラム/関係ガイドラインの開発」班/日本がん・生殖医療研究会編, 金原出版, 東京, 2014
P.163 掲載の参考文献
1) 日本肝臓学会 : B型肝炎治療ガイドライン 第2.1版, 2015
2) 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン, 2011
3) 肝炎ウイルスマーカー・肝機能検査法の選択基準. 日本消化器病学会関連研究会肝機能研究班編, 文光堂, 東京, 2007
4) Nakamura Y, Motokura T, Fujita A et al : Severe hepatitis related to chemotherapy in 109 hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 78 : 2210-2215, 1996
5) Yeo W, Zee B, Zhong S et al : Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90 : 1306-1311, 2004
P.167 掲載の参考文献
1) Wolf I, Sadetzki S, Catane R et al : Diabetes mellitus and breast cancer. Lancet Oncol 6 : 103-111, 2005
2) Olefsky JM, Kimmerling G : Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 271 : 202-210, 1976
3) 高血圧治療ガイドライン 2014 (JSH 2014), 日本高血圧学会高血圧治療ガイドライン作成委員会編, 日本高血圧学会, 東京, 2014
P.169 掲載の参考文献
1) Session St. Gallen 2015 for Panel FINAL03225
2) Lichtman SM, Hurria A, Cirrincione CT et al : Paclitaxel efficacy and toxicity in older women with metastatic breast cancer : combined analysis of CALGB 9342 and 9840. Ann Oncol 23 : 632-638, 2012
3) Muss HB, Berry DA, Cirrincione C et al : Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer : the Cancer and Leukemia Group B Experience. J Clin Oncol 25 : 3699-3704, 2007
4) がん化学療法 ベスト・プラクティス 第1版, 佐々木常雄編著, 照林社, 東京, 2008
5) ハイリスクがん患者の化学療法ナビゲーター, 高野利実編 メジカルビュー社, 東京, 2013, pp.108-110
6) 澤木正孝 : 高齢者乳がん治療の現状と課題. 腫瘍内科 13 : 198-204, 2014
P.172 掲載の参考文献
1) Wallace WH, Anderson RA, Irvine DS : Fertility preservation for young patients with cancer : who is at risk and what can be offered? Lancet Oncol 6 : 209-218, 2005
2) Moore HC, Unger JM, Phillips KA et al : Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372 : 923-932, 2015
3) Loren AW, Mangu PB, Beck LN et al : Fertility preservation for patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31 : 2500-2510, 2013
4) 乳癌薬物療法, 木下貴之, 戸井雅和編, 南山堂, 東京, 2013, pp.378
5) Moore HC, Unger JM, Phillips KA et al : Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372 : 923-932, 2015
P.173 掲載の参考文献
1) ハイリスクがん患者の化学療法ナビゲーター, 高野利美編, メジカルビュー社, 東京, 2013, pp.82
2) 横山顕 : アルコール分解酵素の遺伝子型と生活習慣に基づく食道癌リスク評価. 日がん検診断会誌 21 : 134-140, 2013
3) 抗がん薬の臨床薬理, 相羽恵介編, 南山堂, 東京, 2013, pp.326-335
4) Sparano JA, Zhao F, Martino S et al : Presented at : San Antonio Breast Cancer Symposium 2014. Dec. 9-13, 2014 ; San Antonio, TX.
P.175 掲載の参考文献
1) Hortobagyi GN, Theriault RL, Porter L et al : Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 : 1785-1791, 1996
2) Rosen LS, Gordon DH, Dugan W Jr et al : Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100 : 36-43, 2004
3) Stopeck AT, Lipton A, Body JJ et al : Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol 28 : 5132-5139, 2010
4) 骨転移診療ガイドライン, 日本臨床腫瘍学会編, 南江堂, 東京, 2015
5) Ruggiero SL, Dodson TB, Fantasia J et al : American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Merillofac Surg 72 : 1938-1956, 2014
6) Bamias A, Kastritis E, Bamia C et al : Osteonecrosis of the jaw in cancer after treatment with bisphosphonates : incidence and risk factors. J Clin Oncol 23 : 8580-8587, 2005
7) Lo JC, O'Ryan FS, Gordon NP et al : Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68 : 243-253, 2010
8) Ripamonti CI, Maniezzo M, Campa T et al : Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20 : 137-145, 2009
P.178 掲載の参考文献
1) Lin NU, Carey LA, Liu MC et al : Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26 : 1993-1999, 2008
2) Kelly CM, Juurlink DN, Gomes T et al : Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen : a population based cohort study. BMJ 340 : c693, 2010
3) Gage BF, Edy CS : The genetics of vitamin K antagonists. Pharmacogenomics J 4 : 224-225, 2004
4) Camidge R, Reigner B, Cassidy J et al : Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 23 : 4719-4725, 2005
5) Shah SR, Martin R, Dowell JE et al : Comparison of the 5-fluorouracil-warfarin and capecitabine-warfarin drug interactions. Pharmacotherapy 30 : 1259-1265, 2010
6) 渡辺秀紀, 伊藤弘人, 土屋欣之ほか : S-1とワルファリンの併用によりワルファリンの作用が増強した1例. 癌と化療 42 : 131-133, 2015
最近チェックした商品履歴
Loading...
販売価格 1,210 円（税込）
Part. 1 乳がん薬物療法の基本
-
Part. 1 乳がん薬物療法の基本P.11
-
1. 治療の目的は何か ( 何を目的としておこなうのか, どう適切に実施するか )P.12
-
2. がん化学療法を継続し, 適正におこなうことの重要性P.16
-
3. 術前薬物療法の役割P.20
Part. 2 具体的なレジメンとその解説
-
Part. 2 具体的なレジメンとその解説P.47
-
略語一覧P.48
-
< 初期治療 >P.49
-
レジメン解説P.49
Part. 3 適切な治療マネジメントのポイント
-
Part. 3 適切な治療マネジメントのポイントP.127
-
副作用の原因薬剤一覧表P.128
-
A. 副作用P.130
-
1. 骨髄抑制P.130